Supernus Pharmaceuticals filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company focused on central nervous system diseases. Recent Form 8-K reports cover operating results, conference-call related earnings releases, material definitive agreements, executive compensation arrangements, and other material events tied to the company's CNS product portfolio and corporate obligations.
Proxy materials describe annual meeting voting matters, director elections, advisory executive compensation votes, auditor ratification, and equity incentive plan amendments. The filings also identify the company's common stock structure, exchange listing, shareholder voting mechanics, governance practices, and capital-structure disclosures.
Jack A. Khattar, President, CEO and a director of Supernus Pharmaceuticals (SUPN), reported multiple stock option exercises and subsequent sales executed on 08/06/2025 under a 10b5-1 trading plan adopted September 15, 2022. The filing shows exercises converting employee stock options into common shares (three exercises totaling 201,250 shares: two at a $12.98 exercise price and one at $25.30) and concurrent open-market sales of common stock totaling 140,000 shares at weighted-average prices of approximately $40.24, $42.00 and $43.12 (ranges provided in footnotes).
Following the reported transactions the reporting person is shown as directly beneficially owning 1,069,933 shares and indirectly owning 1,005,600 shares through the KBT Trust. The Form 4 also lists remaining employee stock option holdings reflected as 195,000, 135,000 and 243,750 derivative securities following the transactions.